Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 27 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Cost-effectiveness of treatments for chronic Hepatits B

Neither lamivudine nor adefovir is cost-effective for chronic Hep B, however, reserving adefovir only for lamivudine-associated viral resistance may be highly cost-effective whilst interferon therapy may still be preferred, reports May's issue of Annals of Internal Medicine.

News image

fiogf49gjkf04

Treatment options for chronic Hepatitis B virus infection have disparate risks and benefits.

Interferon has clinically significant side effects, and lamivudine is associated with viral resistance.

In contrast, adefovir is safe and has lower viral resistance but is more expensive, but the most cost-effective approach is uncertain.

Dr Kanwal and colleagues from New York determined whether and under what circumstances the improved efficacy of adefovir offsets its increased cost compared with lamivudine or interferon.

The investigators conducted a cost–utility analysis stratified by Hepatitis B e-antigen status and a systematic review of MEDLINE from 1970 to 2005.

Interferon cost $6337 versus $8446 with adefovir salvage strategy to gain 1 quality-adjusted life-year
Annals of Internal Medicine

The researchers included patients with chronic Hepatits B infection, elevated aminotransferase levels, and no cirrhosis.

The analysis included third-party payer over the lifetime of patients and assessed incremental cost per quality-adjusted life-year gained.

The team classified interventions into 5 groups including no HBV treatment (the “do nothing” strategy) and interferon monotherapy.

The researchers reported that the remaining 3 intervention groups included lamivudine monotherapy, adefovir monotherapy, or lamivudine with crossover to adefovir upon resistance ("adefovir salvage" strategy).

The team found that the "do nothing" strategy was least effective yet least expensive.

The researchers noted that, compared with the "do nothing" strategy, using interferon cost an incremental $6337 to gain 1 additional quality-adjusted life-year.

Compared with interferon, the adefovir salvage strategy cost an incremental $8446 per quality-adjusted life-year gained.

The investigators observed that both the lamivudine and adefovir monotherapy strategies were more expensive yet less effective than the alternative strategies and were therefore dominated.

The team showed in a sensitivity analysis, that interferon was most cost-effective in health care systems with tight budgetary constraints and a high prevalence of Hepatitis B e-antigen-negative patients.

The researchers indicated that these results apply only to patients with chronic Hepatitis B infection with elevated aminotransferase levels, and no clinical or histologic evidence of cirrhosis.

The research team reported that these results do not apply to alternative populations to those with Hepatitis B as described.

Dr Kanwal's team concludes, “Neither lamivudine nor adefovir monotherapy is cost-effective in chronic Hepatitis B infection.”

“However, a hybrid salvage strategy reserving adefovir only for lamivudine-associated viral resistance may be highly cost-effective across most health care settings.”

“Interferon therapy may still be preferred in health care systems with limited resources, especially in those serving populations with a high prevalence of Hepatitis B e antigen-negative.”

Ann Int Med 2005: 142(10): 821-831
18 May 2005

Go to top of page Email this page Email this page to a colleague

 25 May 2018 
Colorectal cancer–specific mortality
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Post‐operative complications in elderly IBD
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us